ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2020 and some content may be unavailable. To unlock all content for 2020, please visit the archives.

Abstract: PO1096

Endothelin 1 and Parameters of Systolic Blood Pressure in Hemodialysis Patients

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Singh, Anika T., Harvard Medical School, Boston, Massachusetts, United States
  • Sarvode mothi, Suraj, Brigham and Women's Hospital, Boston, Massachusetts, United States
  • Li, Ping, Chinese PLA General Hospital, Beijing, Beijing, China
  • Waikar, Sushrut S., Boston Medical Center, Boston, Massachusetts, United States
  • McCausland, Finnian R., Brigham and Women's Hospital, Boston, Massachusetts, United States

Group or Team Name

  • Mc Causland Lab
Background

Blood pressure (BP) fluctuates widely during intermittent hemodialysis (HD), with greater variability associated with adverse cardiovascular outcomes. As endothelin-1 (ET-1) is a potent vasoconstrictor, we hypothesized that higher concentrations of ET-1 is associated with higher pre-HD systolic BP (SBP).

Methods

ET-1 concentrations were measured at baseline from the DaVita Biorepository (N=784), a longitudinal prospective cohort study with quarterly collection of clinical data and biospecimens. Unadjusted and adjusted linear mixed effects regression models were fit to determine associations of log-transformed ET-1 with SBP at dialysis (pre-HD, nadir intra-HD, post-HD, drop (pre- minus nadir-HD) and delta (pre- minus post-HD). Multivariable models were adjusted for age, sex, race, access, diabetes, heart failure, cardiovascular disease, peripheral vascular disease and pre-HD SBP.

Results

Mean age was 58 years, 59% were males, 40% black. Mean pre-HD SBP was 152 (± 28) mmHg and mean ET-1 concentration was 2.3 (±1.1) ng/mL. Subjects in higher quartiles of baseline ET-1 tended to be younger, diabetic, have higher SBP and lower serum albumin. In fully adjusted models, each unit increase in SD of log-transformed ET-1 was associated with a 3.0 (95% CI 1.8 to 4.2) mmHg higher pre-SBP; 1.2 (95%CI 0.5 to 1.9) mmHg higher nadir-SBP; 1.6 (95% CI 0.6 to 2.5) mmHg higher post-SBP; 1.2 (95%CI 0.2 to 1.5) mmHg lower SBP drop and 1.6 mmHg (95% CI 0.6 to 1.08) lower delta SBP. In categorical analyses a monotonic increase in pre-SBP was noted in higher quartiles of ET-1 (Q4: 7.8 mmHg increase (95% CI 4.5 to 11.2; P<0.001) compared with Q1. Similar patterns were noted for the other variables of interest.

Conclusion

Higher ET-1 is independently associated with higher SBP in maintenance HD patients. These results suggest a role for studying ET-1 antagonism in HD patients with resistant hypertension.